Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: A systematic review and meta‐analysis
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Atomoxetine is prescribed to children with autism spectrum disorder having symptoms of attention deficit hyperactivity disorder. We sought to examine the efficacy and safety of atomoxetine in this population. After screening for inclusion criteria, we identified three randomized placebo controlled trials involving 241 children. We assessed internal validity using standard Cochrane Risk of bias tool for randomized controlled trials (RCTs). We used Revman 5.3 for meta‐analysis and GRADE approach to create summary of findings with grading of the quality of evidence. Atomoxetine had a benefit on improving parent‐rated hyperactivity (standardized mean difference [SMD] = −0.73, 95% Confidence Interval, CI = −1.15 to −0.34) and parent‐rated inattention (SMD = −0.53, 95% CI = −0.93 to −0.12) but the magnitude of effects is uncertain. However, atomoxetine was also associated with increased risk of non‐serious adverse effects like nausea and vomiting, decreased sleep, and decreased appetite. Atomoxetine may be effective in improving hyperactivity and inattention in children with autism spectrum disorder and attention deficit hyperactivity disorder. However, we are uncertain about the true effect of this intervention and need more RCTs trials designed to evaluate this. Autism Research 2019, 12: 542–552. © 2019 International Society for Autism Research, Wiley Periodicals, Inc. Lay Summary: Atomoxetine is prescribed for Attention Deficit Hyperactivity Disorder (ADHD). About a third of children and adolescents with autism also suffer from ADHD. We carried out an analysis of data reported from a specific kind of medication trials which had examined the effectiveness and side effects of atomoxetine in this patient population. We could find only three such trials and analyzed the reported data. Our analysis revealed that atomoxetine is effective in improving symptoms of ADHD like hyperactivity and inattention and also causes side effects like nausea, vomiting, decreased sleep, and decreased appetite. However, the existing data are insufficient to provide a conclusive statement with certainty and more trials are needed for this.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Industry sponsorship and research outcome
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub3 · Cited by 1,697
Comorbid psychiatric disorders in children with autism: interview development and rates of disorders
Leyfer, O. T., Folstein, S. E., Bacalman, S., Davis, N. O., Dinh, E., Morgan, J., Tager-Flusberg, H., & Lainhart, J. E. (2006) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0123-0 · Cited by 1,637 · cited 1×
“ADHD is the third common comorbidity and is diagnosed in 37–85% of children with ASD [Gadow, DeVincent, & Pomeroy, 2006; Leyfer et al., 2006].”
Background(2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.11.1266 · Cited by 521
Gadow, K. D., Devincent, C. J., Pomeroy, J., & Azizian, A. (2005) · Autism · doi:10.1177/1362361305056079 · Cited by 388 · cited 1×
“Stimulants can exacerbate stereotypies, tics, selfinjury, and anxiety in children with ASD [Aman et al., 2004; Arnold et al., 2006; Gadow et al., 2005].”
BackgroundADHD and autism: differential diagnosis or overlapping traits? A selective review
Taurines, R., Schwenck, C., Westerwald, E., Sachse, M., Siniatchkin, M., & Freitag, C. (2012) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-012-0086-2 · Cited by 301
Yerys, B. E., Wallace, G. L., Sokoloff, J. L., Shook, D. A., James, J. D., & Kenworthy, L. (2009) · Autism Research · doi:10.1002/aur.103 · Cited by 299 · cited 1×
“Co-morbid ADHD often results in lower cognitive, adaptive, and social functioning [Rao & Landa, 2014; Yerys et al., 2009].”
BackgroundExamining autistic traits in children with ADHD: does the autism spectrum extend to ADHD?
Grzadzinski, R., Di Martino, A., Brady, E., Mairena, M. A., O’Neale, M., Petkova, E., Lord, C., & Castellanos, F. X. (2011) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-010-1135-3 · Cited by 260 · cited 1×
“Impulsivity which is a core symptom of ADHD might contribute to inappropriate intrusiveness; however, even after treatment of ADHD social difficulties in getting along with friends and siblings and expressing affection persist [Grzadzinski et al., 2011].”
BackgroundAtomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial
ARNOLD, L. E., AMAN, M. G., COOK, A. M., WITWER, A. N., HALL, K. L., THOMPSON, S., & RAMADAN, Y. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000231976.28719.2a · Cited by 260 · cited 6×
“Stimulants can exacerbate stereotypies, tics, selfinjury, and anxiety in children with ASD [Aman et al., 2004; Arnold et al., 2006; Gadow et al., 2005].”
BackgroundMethodInfluentialADHD symptom subtypes in children with pervasive developmental disorder
Gadow, K. D., DeVincent, C. J., & Pomeroy, J. (2006) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-005-0060-3 · Cited by 233
Craig, F., Lamanna, A. L., Margari, F., Matera, E., Simone, M., & Margari, L. (2015) · Autism Research · doi:10.1002/aur.1449 · Cited by 194
Grzadzinski, R., Dick, C., Lord, C., & Bishop, S. (2016) · Molecular Autism · doi:10.1186/s13229-016-0072-1 · Cited by 192
Harfterkamp, M., van de Loo-Neus, G., Minderaa, R. B., van der Gaag, R.-J., Escobar, R., Schacht, A., Pamulapati, S., Buitelaar, J. K., & Hoekstra, P. J. (2012) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2012.04.011 · Cited by 171 · cited 3×
“In the three RCTs, total participants were 241 with n = 16 in first trial, n = 97 in second trial and (n = 128) in third trial [Arnold et al., 2006; Handen et al., 2015; Harfterkamp et al., 2012].”
BackgroundMethodSchwartz, S., & Correll, C. U. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.11.005 · Cited by 166
Handen, B. L., Aman, M. G., Arnold, L. E., Hyman, S. L., Tumuluru, R. V., Lecavalier, L., Corbett-Dick, P., Pan, X., Hollway, J. A., Buchan-Page, K. A., et al. (2015) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2015.08.013 · Cited by 147
Sokolova, E., Oerlemans, A. M., Rommelse, N. N., Groot, P., Hartman, C. A., Glennon, J. C., Claassen, T., Heskes, T., & Buitelaar, J. K. (2017) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-017-3083-7 · Cited by 136 · cited 1×
“Causal and mediational analyses have identified multiple pathways between ASD and ADHD with specific targets for interventions [Sokolova et al., 2017].”
BackgroundReichow, B., Volkmar, F. R., & Bloch, M. H. (2013) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-013-1793-z · Cited by 134
Dalsgaard, S., Nielsen, H. S., & Simonsen, M. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0111 · Cited by 119
Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders
Aman, M. G., Farmer, C. A., Hollway, J., & Arnold, L. E. (2008) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2008.06.009 · Cited by 82
Bachmann, C. J., Manthey, T., Kamp-Becker, I., Glaeske, G., & Hoffmann, F. (2013) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2013.05.028 · Cited by 63
Charnsil, C. (2011) · Journal of Attention Disorders · doi:10.1177/1087054710376907 · Cited by 36
Cited by
The Lancet Commission on the future of care and clinical research in autism
Lord, C., Charman, T., Havdahl, A., Carbone, P., Anagnostou, E., Boyd, B., Carr, T., de Vries, P. J., Dissanayake, C., Divan, G., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01541-5 · Cited by 924
Solmi, M., Fornaro, M., Ostinelli, E. G., Zangani, C., Croatto, G., Monaco, F., Krinitski, D., Fusar‐Poli, P., & Correll, C. U. (2020) · World Psychiatry · doi:10.1002/wps.20765 · Cited by 324
Rodrigues, R., Lai, M., Beswick, A., Gorman, D. A., Anagnostou, E., Szatmari, P., Anderson, K. K., & Ameis, S. H. (2021) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.13305 · Cited by 98
Fu, D., Wu, D.-D., Guo, H.-L., Hu, Y.-H., Xia, Y., Ji, X., Fang, W.-R., Li, Y.-M., Xu, J., Chen, F., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.780921 · Cited by 66
Lilja, M. M., Sandblom, E., Lichtenstein, P., Serlachius, E., Hellner, C., Bhagia, J., & Halldner, L. (2022) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-022-09424-2 · Cited by 14
“We did not aim to answer the question whether there was a difference in efficacy amidst different substances between the groups, which is indicated in other studies [15, 20, 24, 28, 49].”
Result
Metadata
- Authors
- Patra, S., Nebhinani, N., Viswanathan, A., & Kirubakaran, R.
- Venue
- Autism Research
- Publisher
- Wiley
- Published
- 2019-01-17
- Volume
- 12
- Issue
- 4
- Pages
- 542-552
- ISSN
- 1939-3792 (ISSN-L)
- 1939-3806
- OpenAlex
- W2909627213
- Cited by
- 46
- References
- 20
- FWCI
- 1.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.